Dr. Laura Hall -- Pharma Payment Report

Payment Summary

• Total Payments Received: $1,433.45
• Number of Transactions: 1
• Transparency Score: 50/100

Payment Breakdown

• speaking: $0.00
• travel: $1,433.45
• ownership: $0.00
• consulting: $0.00
• research: $0.00
• meals: $0.00

AI Analysis

Dr. Laura Hall, a General Surgeon in Detroit, MI, has a pharmaceutical payment profile characterized by a single, relatively small payment totaling $1433.45. This payment was received from Johnson & Johnson and was designated for travel, occurring on March 22, 2026. When compared to the broader landscape of General Surgery, Dr. Hall's total payment volume is exceptionally low. The average general surgeon may receive payments ranging from a few thousand to tens of thousands of dollars annually, often spread across multiple companies and payment types, including consulting fees, speaking engagements, meals, and research grants. Dr. Hall's single payment from Johnson & Johnson, while specific, does not represent a significant financial relationship that would typically raise concerns about undue influence. The nature of the payment as 'travel' suggests it may be related to attending a conference, presenting research, or participating in an advisory board meeting, which are common forms of professional engagement between physicians and pharmaceutical companies. However, without more detailed information on the purpose of the travel, it's difficult to definitively categorize its intent. The limited nature of this payment suggests that Dr. Hall's professional activities are not heavily subsidized by pharmaceutical manufacturers. This pattern does not inherently suggest routine professional activity that warrants closer attention, nor does it indicate a lack of engagement with industry advancements. For patients, these payments, especially when minimal and transparently reported, generally do not directly impact the quality of care received. However, it is always prudent for patients to be aware of potential conflicts of interest, however small. Understanding that physicians may receive payments for various professional services is important, but the key lies in the transparency and magnitude of these relationships. Dr. Hall's profile, with its single, modest payment, presents a picture of minimal financial ties to the pharmaceutical industry, which can be reassuring for patients seeking objective medical advice.

Patient Guidance

When considering your doctor's relationships with pharmaceutical companies, it's helpful to remember that some level of interaction is common and can be beneficial for staying updated on new treatments. However, transparency is key. At your next appointment, you might consider asking your doctor if they have any financial relationships with companies whose medications they prescribe. Red flags to watch for include a doctor who consistently prescribes a specific brand-name drug without a clear clinical justification, especially if they have significant financial ties to that drug's manufacturer. Normal interactions often involve payments for legitimate professional services like speaking at educational events or participating in research. Concerning relationships might involve large, frequent payments for vague services, or a pattern of prescribing that seems heavily influenced by industry incentives. To evaluate your doctor's prescribing patterns, look for consistency in treatment recommendations across different drug options and consider seeking a second opinion if you have concerns about the appropriateness of prescribed medications, particularly if you become aware of substantial financial ties.

Peer Comparison

Dr. Hall's total pharmaceutical payments of $1433.45 are significantly lower than the average for General Surgeons. While payment amounts vary widely, many general surgeons receive annual payments that can range from several thousand to tens of thousands of dollars from various pharmaceutical companies for activities like consulting, speaking, and research. Dr. Hall's single payment places her well below the typical range, indicating minimal financial engagement with the industry compared to her peers.

Recent Payments

Frequently Asked Questions

Is Dr. Laura Hall taking too much pharma money?

Based on the available data, Dr. Laura Hall has received a single payment of $1433.45 for travel from Johnson & Johnson. This amount is exceptionally low when compared to the average payments received by General Surgeons, which can often be in the thousands or tens of thousands of dollars annually. Therefore, her current payment profile does not suggest she is taking an excessive amount of pharmaceutical money. The transparency of this single payment also contributes to a low-risk profile in this regard.

What pharma companies pay Dr. Laura Hall?

Dr. Laura Hall has received payments from one pharmaceutical company: Johnson & Johnson, totaling $1433.45.

Should I switch doctors because of pharma payments?

Switching doctors solely based on pharmaceutical payments should be a nuanced decision. Dr. Hall's payment profile is minimal, with a single travel-related payment. Generally, minor payments for legitimate professional services are not a reason to switch. However, if you observe a pattern of your doctor heavily favoring specific, expensive brand-name drugs without clear justification, or if they are reluctant to discuss alternatives, and you discover significant financial ties to those drug manufacturers, then it might be a cause for concern and warrant further investigation or a second opinion.

What kinds of payments does this doctor receive?

Dr. Laura Hall has received one type of payment: travel, totaling $1433.45 from Johnson & Johnson. This specific payment was for travel, suggesting it may be related to attending a conference, participating in an advisory board, or other industry-sponsored educational events.

How do these payments compare to other General Surgery?

Dr. Hall's total pharmaceutical payments of $1433.45 are significantly lower than the average for General Surgeons. Many surgeons in this specialty receive substantially more, often in the thousands or tens of thousands of dollars annually, distributed across various payment types. Her profile indicates minimal financial engagement with pharmaceutical companies compared to her peers.

Do pharma payments affect prescribing quality?

Research suggests that even small payments can influence physician prescribing habits, potentially leading to increased prescription of the paying company's drugs. However, the impact varies greatly depending on the type and amount of payment, as well as the individual physician. For Dr. Hall, with only a single, modest travel payment, the likelihood of significant influence on prescribing quality is low, but it remains a factor to consider in the broader context of physician-industry relationships.

How can I verify this payment data?

You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. This publicly accessible website allows you to search for physicians by name or NPI number (1578193359 for Dr. Laura Hall) and view detailed records of payments and other transfers of value made by pharmaceutical and medical device companies.